A Phase 2 dose-ranging study of IONIS APOCIII LRx in patients with hypertriglyceridemia and established cardiovascular disease .
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs IONIS APOCIII LRx (Primary)
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Adverse reactions; Therapeutic Use
- 08 Aug 2017 Accordign to an Akcea Therapeutics media release, the company plans to initiate this study in the second half of 2017.
- 09 May 2017 Accordign to an Ionis Pharmaceuticals media release, the company plans to initiate this study later in 2017
- 12 Jan 2017 New trial record